Cytochrome P450 (CYP) 1A2, sulfotransferase (SULT) 1A1, and N-acetyltransferase (NAT) 2 polymorphisms and susceptibility to urothelial cancer

被引:32
作者
Tsukino, H
Kuroda, Y
Nakao, H
Imai, H
Inatomi, H
Osada, Y
Katoh, T
机构
[1] Miyazaki Univ, Miyazaki Med Coll, Dept Publ Hlth, Miyazaki 8891692, Japan
[2] Miyazaki Univ, Miyazaki Med Coll, Dept Urol, Miyazaki, Japan
[3] Munakata Suikoukai Gen Hosp, Munakata 8113298, Japan
关键词
CYP1A2; SULT1A1; NAT2; polymorphism; urothelial cancer;
D O I
10.1007/s00432-003-0512-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose. Arylamines are suspected to be the primary causative agent of urothelial cancer in tobacco smoke. In the human liver, arylamines are N-hydroxylated by a cytochrome P450 (CYP)1A2-catalyzed reaction, which produces a substrate for O-esterification that can be catalyzed by N-acetyltransferases (NAT) or sulfotransferases (SULT). Recently, several polymorphisms of CYP1A2, SULT1A1, and NAT2 that affect their activities have been reported. Methods. In this study, 306 Japanese patients with urothelial transitional cell carcinoma and 306 healthy controls were compared for frequencies of CYP1A2, SULT1A1, and NAT2 genotypes. Results. The frequencies of NAT2 intermediate or slow acetylator genotype were significantly higher in the urothelial cancer patients than in the healthy control subjects [odds ratio (OR)=1.49, 95% confidence interval (95% CI) 1.06-2.09, OR=3.23, 95% CI 1.72-6.08, respectively]. Stratifying by amount of smoking, among subjects who consumed >33.5 pack-years and carried the SULT1A1 *1/*1 or NAT2 slow acetylator genotype, the OR was 1.73 (95% CI 1.01-2.97) whereas it was 7.31 (95% CI 1.90-28.05) in non-smokers who carried the homozygous wild genotype, respectively. The relationships between CYP1A2, SULT1A1, and NAT2 polymorphisms and clinical findings including tumor differentiation, stage, and recurrence rate were analyzed. Only associations between NAT2 genotype and pathological findings were admitted, and the higher OR of NAT2 intermediate and slow acetylator genotype was more likely to present to a low-grade tumor (G1) among heavy-smokers. Conclusions. Our results suggest that SULT1A1 *1/*1 and NAT2 slow acetylator genotypes might modulate the effect of carcinogenic arylamines contained in tobacco smoke, and that the modulation of NAT2 intermediate and slow acetylator genotype has a tendency to present a higher risk for highly differentiated tumors among heavy-smokers.
引用
收藏
页码:99 / 106
页数:8
相关论文
共 48 条
[1]   Does smoking status influence the prognosis of bladder cancer? A systematic review [J].
Aveyard, P ;
Adab, P ;
Cheng, KK ;
Wallace, DMA ;
Hey, K ;
Murphy, MFG .
BJU INTERNATIONAL, 2002, 90 (03) :228-239
[2]   CARCINOGEN HEMOGLOBIN ADDUCTS, URINARY MUTAGENICITY, AND METABOLIC PHENOTYPE IN ACTIVE AND PASSIVE CIGARETTE SMOKERS [J].
BARTSCH, H ;
CAPORASO, N ;
CODA, M ;
KADLUBAR, F ;
MALAVEILLE, C ;
SKIPPER, P ;
TALASKA, G ;
TANNENBAUM, SR ;
VINEIS, P .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (23) :1826-1831
[3]   BLACK (AIR-CURED) AND BLOND (FLUE-CURED) TOBACCO CANCER RISK .4. MOLECULAR DOSIMETRY STUDIES IMPLICATE AROMATIC-AMINES AS BLADDER CARCINOGENS [J].
BARTSCH, H ;
MALAVEILLE, C ;
FRIESEN, M ;
KADLUBAR, FF ;
VINEIS, P .
EUROPEAN JOURNAL OF CANCER, 1993, 29A (08) :1199-1207
[4]   GENOTYPE-PHENOTYPE DISCORDANCE FOR HUMAN ARYLAMINE N-ACETYLTRANSFERASE (NAT2) REVEALS A NEW SLOW-ACETYLATOR ALLELE COMMON IN AFRICAN-AMERICANS [J].
BELL, DA ;
TAYLOR, JA ;
BUTLER, MA ;
STEPHENS, EA ;
WIEST, J ;
BRUBAKER, LH ;
KADLUBAR, FF ;
LUCIER, GW .
CARCINOGENESIS, 1993, 14 (08) :1689-1692
[5]   298 K rate coefficients for the reaction of OH with i-C3H7I, n-C3H7I and C3H8 [J].
Carl, SA ;
Crowley, JN .
ATMOSPHERIC CHEMISTRY AND PHYSICS, 2001, 1 :1-7
[6]  
CARTWRIGHT RA, 1982, LANCET, V2, P842
[7]  
Chevalier D, 2001, Hum Mutat, V17, P355, DOI 10.1002/humu.48
[8]   Detection of three genetic polymorphisms in the 5′-flanking region and intron 1 of human CYP1A2 in the Japanese population [J].
Chida, M ;
Yokoi, T ;
Fukui, T ;
Kinoshita, M ;
Yokota, J ;
Kamataki, T .
JAPANESE JOURNAL OF CANCER RESEARCH, 1999, 90 (09) :899-902
[9]   Epidemiology and etiology of premalignant and malignant urothelial changes [J].
Cohen, SM ;
Shirai, T ;
Steineck, G .
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 2000, 34 :105-115
[10]   Metabolism of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine by human cytochrome P4501A1, P4501A2 and P4501B1 [J].
Crofts, FG ;
Sutter, TR ;
Strickland, PT .
CARCINOGENESIS, 1998, 19 (11) :1969-1973